A Korean multicenter study was conducted to assess the effectiveness of transurethral alprostadil with MUSE in 334 subjects with chronic erectile dysfunction (ED) who were enrolled in 21 clinical centers. Patients with psychogenic impotence comprised about 30% of subjects. Intraurethral alprostadil was titrated in a stepwise fashion in the clinics from 250 to 500 or 1000 mcg based on erectile response and tolerability. The erectile responses were evaluated using an erection assessment scale (score of 1±5). The dose that produced a maximal penile response of score 5 (full rigid erection) or 4 (full tumescence, partial rigidity) was selected for home treatment. Patients who showed partial erection (score of 3) with 1000 mcg were also included in the home-treatment group.
Introduction
Intracavernous injection of vasoactive medication has been used successfully for over 10 years for the treatment of erectile dysfunction (ED). 1, 2 Despite the ef®cacy of intracavernous pharmacotherapy, longterm dropout rate with time is high. 3±5 One of the main reasons for discontinuation is dislike of the injection. Recently, transurethral alprostadil using the medicated urethral system for erection (MUSE; VIVUS, USA) has been introduced as a less invasive alternative treatment. 6 The MUSE is a novel system designed to administered alprostadil (PGE 1 ) topically to the urethral mucosa for the treatment of ED. The needleless application offers signi®cant potential bene®ts. The multicenter trials to assess the effectiveness of MUSE showed encouraging ef®cacy rates from USA 6 and Europe, 7 although there have also been disappointing results. 8 We performed a unique Korean multicenter trial to assess the requirement for in-clinic titration and the effectiveness of transurethral alprostadil using MUSE in 334 men with ED.
Materials and methods
Three hundred and thirty four men with a subjective complaint of chronic ED were enrolled in 21 clinical centers (10±20 subjects per center) in Korea. They underwent a diagnostic evaluation with patient history, physical examination, determination of serum testosterone, glucose level, lipid pro®le, and liver function test. They were provided with informed consent, questionnaires on quality of erection and life, and instructional materials. Exclusion criteria were history of urethral stricture or obstruction; acute or chronic urethritis; an indwelling urethral catheter; anuria; a penile implant; paraplegia; sickle cell disease; multiple myeloma; congestive heart failure, acute myocardial infarction within 6 months, or unstable angina. Men were also excluded from the study if they had participated in an investigational drug evaluation within the proceeding 30 days, or had signi®cantly abnormal blood chemistry, hematologic, or hormonal testing results. Intraurethral alprostadil was administered in clinic by the same urologist in each center and titrated in a stepwise fashion every other day from 250 to 500 or 1000 mcg based on erectile response (erection suf®cient for sexual intercourse) and tolerability. The erectile responses were evaluated with an erection assessment scale (score of 1±5) as suggested in the MUSE studies. 6 Scores were assigned by the investigators. Patients with an erection score 5 (full rigid erection) and 4 (full tumescence, partial rigidity but suf®cient for intercourse) were considered as responders. When the patients produced an erection of score 5 or 4 with 250 or 500 mcg, no more doses were tested. The dose that produced a maximal penile response of 4 or 5 was selected for home treatment. Patients who showed partial erection (score of 3) with 1000 mcg were also included in home treatment group. The men who showed a good erectile response but did not tolerate the treatment were discharged from the study. The duration of the penile response was also recorded, and each man rated his overall level of comfort from`very comfortable' to`very uncomfortable'. Blood pressure and pulse rate were monitored for 60 min after administration of alprostadil.
Patients achieving an erection suf®cient for intercourse, or a partial erection, using 1000 mcg advanced to home treatment with their selected dose for two months. After each administration of the treatment, the man made entry in a diary that documented the penile response, the occurrence of sexual intercourse, the overall level of comfort associated with the use of the medication, and any adverse effects noted by the man and his partner. After home treatment of two months, the same laboratory tests except for serum testosterone were performed and the diaries were reviewed. Quality of life was also measured.
Statistical analysis
The response rate during home treatment was estimated by dividing the number of subjects who reported sexual intercourse at least once by the total number of subjects. A 95% con®dence interval was estimated. Response rates according to age distribution, in-clinic titration testing, and home-treatment phase were compared by chi-square test. The difference in a patient's quality of life before and after treatment was assessed by paired t-test. SAS software (version 6.12) was used in all statistical analyses. The analysis of the ef®cacy of in-clinic testing included all men who received at least one dose in the clinic. The analysis of the ef®cacy at home included all men who reported at least one administration of transurethral alprostadil, and the analysis of safety included all men enrolled in the study.
Results

Demographics
The characteristics of 228 men who began home treatment were similar to those of 334 men tested in the clinic with regard to mean age, primary etiology and the duration of ED (Table 1) . Patients with psychogenic impotence comprised about 30%. Patients with organic impotence had one or more underlying diseases of which diabetes mellitus and hypertension were the most common, followed by traumaasurgery, neurologic disease, side effects of medication, and hypogonadism.
In-clinic phase
The erectile response rates in the clinic according to the etiology of ED are shown in Table 2 . Of the 334, 198 (59.3%) had maximal penile responses of score 4 or 5 on the erection assessment scale. The percentage achieving a maximal response of score 4 or 5 was higher in psychogenic impotence (64.0%) than in organic impotence (57.3%) but it was not statistically different (P 0.14). There was no signi®cant difference in the rate of good response Table  3 ). The dose necessary to achieve good erectile response (score 4 or 5) was not signi®cantly different between psychogenic and organic impotence. The interval between the administration of alprostadil and the time to achieve a suitable erection was within 15 min in 47%, 15±30 min in 38.4%, 30± 45 min in 11.6% and 45±60 min in 3%. At least 88% of the men receiving each dose rated the transurethral application of alprostadil at that dose as neutral',`comfortable', or`very comfortable'. The dose was not related to the comfort level (Table 3) .
Home treatment phase
Of the 228 men who had treatment at home, 178 (78.1%) had successful sexual intercourse at least once (Table 4) . During the two-month period of home treatment 78.2% of administrations (1976) resulted in successful intercourse. Transurethral alprostadil was more effective in psychogenic impotence (83.3%) than in organic impotence (75.6%), however, it was not statistically different. The transurethral alprostadil in organic impotence was effective regardless of the underlying etiology of ED and the age of the subject. The longer the duration of ED, the lower was the rate of good response (score 4 or 5) (P 0.02). The dose used to achieve the successful intercourse was 250 mcg in 58 (32.6%), 500 mcg in 50 (28.1%), and 1000 mcg in 70 (39.3%).
The proportion of men who had successful intercourse increased as the dose of alprostadil increased (P 0.003); 250 mcg in 67.4% (58a86), 500 mcg in 78.1% (50a64), and 1000 mcg in 91.0% (71a78).
The mean duration of a suf®cient erection was 22.1 AE 20.8 (1.0±168.3) min. The distribution was less than 5 min in 12.0%; 5±10 min in 16.0%; 10± 20 min in 27.4%; 20±40 min in 32.6%; 40±60 min in 8.0%; more than 60 min in 4.0%. The reasons why the 51 men dropped out during the two-month home phase were insuf®cient erectile response in 27 (11.8%), adverse reactions (mostly penile or urethral pain) in seven (3.1%), adverse reactions with insuf®cient erectile response in seven (3.1%), failure to follow-up in six (2.6%), and others in four (1.8%).
Concerning the quality of life, sex-related items (quality of erection, enjoyment of sexual activity, satisfaction with sexual relationship, feeling pleasure whilst engaging in sexual activity) and items related to general well-being (weariness, happiness, feeling calm and peaceful, feeling downhearted and blue, con®dence, something to look forward to, feeling manly, satisfaction with partner as a human being) were all signi®cantly improved as well as their overall quality of life (P 0.0001).
Adverse effects
Penile or urethral pain was the most common adverse effect during both the clinic phase and the home treatment (Table 5 ). Urethritis developed in 
Discussion
The distal urethral mucosa has proved to be an excellent route for absorption and transfer of vasoactive substances to the corpora cavernosa. This transfer occurs by direct venous communications between the corpus spongiosum and the corpora cavernosa. 9 The transurethral route of vasoactive drug delivery is able to produce peak systolic¯ow velocities of the cavernous arteries similar to that produced by direct intracavernosal injection. 10 MUSE is a newly developed delivery system through which a pellet of alprostadil is inserted into the urethra. According to the ®rst comprehensive overview from USA on the ef®cacy and safety of transurethral alprostadil with MUSE, 65.9% (996a1511) of the patients had erections suf®cient for intercourse (score 4 or 5) during in-clinic titration phase. 6 Of these, 961 men were randomized in a placebo-controlled trial at home, and 64.9% of those treated with alprostadil reported successful intercourse at least once. On average, 70% of the intraurethral alprostadil administrations were followed by intercourse in men responsive to treatment. Similar ef®cacy rates were yielded in the multi-center European MUSE trial. 7 In the clinic titration phase, 64% of the 249 men with chronic ED achieved an erection of score 4 or 5, and 69% of those who achieved an erection suf®cient for intercourse reported successful sexual intercourse during home treatment phase of 3 months. These data both from USA and European short-term multiinstitutional trials indicate that this therapeutic option promises to be an early or ®rst-line therapy because of its relatively noninvasive delivery, acceptable ef®cacy, and safety. In our study, the rate of maximal responses of score 4 or 5 in the clinic (59.3%) was a little lower but the rate of successful intercourse at home was higher (78.1%) than the two multi-center trials. The lower rate of good response in this study might be because intraurethral alprostadil was administered by urologists, which might induce high anxiety, whereas in the other studies it was administered by the patients themselves. Engel and McVary 11 noticed 58% of patients reporting intracavernous injection therapy as`not effective' achieved an erection suf®cient for intercourse following transurethral alprostadil therapy. Our higher rate of successful intercourse at home may be explained by the fact that 31.6% of the patients had psychogenic impotence. Disappointing results with transurethral alprostadil have also been reported. Fulgham et al 9 reported only 13.2% (500 mcg) and 30% (1000 mcg) of patients achieved rigidity suf®cient for intercourse, however, only 10% of their patients were given the highest dose (1000 mcg).
To get the best response to transurethral alprostadil, patients should be educated carefully about its use. The ef®cacy of intraurethral drug delivery systems to induce functional erection is dependent upon the ability of drug transfer from the corpus spongiosum to the corpora cavernosa. Although not formally studied, it may be advisable to administer intraurethral alprostadil before sexual excitation, which results in an increase in intracavernous pressure and may theoretically impair transfer of alprostadil to the corpora cavernosa from the corpus spongiosum. Instillation in the supine posture may be less effective than in the standing or the sitting posture. Consequently, the response rates would depend on how well patients were instructed about the use of MUSE, and how many complete vasculogenic impotence patients were included. This also explains why the rate of good erection suf®cient for erection in the clinic testing of our study was so variable (30±90%) depending on the clinical center.
The dosages required to achieve maximal scores of 4 or 5 would seem to depend on patient age, the etiology and severity of ED. However, the ef®cacy of alprostadil in this study was similar regardless of patient's age and etiology of ED although the longer the duration of erectile dysfunction, the lower was the rate of good erectile response at home. By relying on local rather than systemic delivery, the in¯uence of factors such as age and underlying disease may have been lessened. 6 Compared to intracavernous alprostadil, intraurethral alprostadil dose requirements are much higher, but it appears to cause less priapism and penile ®brosis, and uncommonly systemic effects. Penile Multicenter study of the treatment of ED using MUSE SC Kim et al pain was the most common adverse effect reported during clinic testing (4.8%) and home treatment (6.1%) followed by urethral pain (3.3 and 3.9%, respectively). Pain was a reason given for withdrawal from the study. Padma-Nathan et al 6 reported penile pain after 10.8% of the treatments but it rarely resulted in the withdrawal from their study. The delivery system was well accepted, as indicated by the favorable comfort ratings (Table 3) . No priapism, urethral bleeding, or penile ®brosis were observed, and urethritis (0.9%) was uncommon. Clinically relevant systemic side-effects such as dizziness and¯ushing were observed in 1.5% during in-clinic testing and 0.8% during home treatment, but hypotension did not occur. In ongoing clinical trials on 2595 patients and with a follow-up period of between 6 and 24 months, penile pain occurred in 29% of the patients, urethral bleeding in 5%, dizziness in 2%, ®brosis in 1% and priapism in less than 0.1%. 12 The most common side effect was penile pain which rarely resulted in study discontinuation. Recently, Hellstrom et al 13 reported a long-term study over a 1 y home treatment period. Of the 22 786 administrations in 983 patients with ED, 73% resulted in successful sexual intercourse. The most common adverse effects were penile pain in 29% of patients and minor urethral pain in 12% of patients. Most patients and partners were`somewhat satis®ed' or`very satis®ed' with this therapy. According to the European multicenter study, 7 the most common adverse reaction in the clinic was urethral painaburning (7%) followed by penile pain (4%). Most patients (83%) graded transurethral alprostadil as causing minimal or no discomfort in the clinic. In contrast to these favorable reports, including this study, Fulgham et al 8 reported a higher incidence of adverse effects. The authors state that orthostatic hypotension was observed in 41.2%, although no control was provided for these blood pressure changes. A total of 21 (18.3%) patients had adverse events, including pain and discomfort, burning, dizziness, and chest pain. In a comparative study of transurethral and intracavernous alprostadil, 14 penile painaburning-rate after intraurethral alprostadil was 31.4% compared to 10.6% after intracavernous alprostadil. In addition, after MUSE, clinically relevant systemic side-effects such as dizziness, sweating and hypotension occurred in 5.8%.
Conclusion
The ef®cacy and safety pro®le of intraurethral alprostadil with a noninvasive delivery system, MUSE, in our study suggest this new formulation of alprostadil could be a suitable alternative for patients with erectile dysfunction regardless of age, etiology of erectile dysfunction, or race, although long-term follow-up studies will determine patients' compliance and continuation rates.
